» Articles » PMID: 20020140

Willingness to Pay for Improvement of Physical Function Among Rheumatoid Arthritis Patients As Measured by Health Assessment Questionnaire

Overview
Journal Rheumatol Int
Specialty Rheumatology
Date 2009 Dec 19
PMID 20020140
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The main objective of this study was to assess the symptoms and functional difficulties caused by rheumatoid arthritis through application of the willingness to pay (WTP) method. Structured questionnaire study was conducted among 242 RA patients. The subjects were asked to evaluate their functional capacity using visual analog scales (VAS) for all the 20 questions in the Health Assessment Questionnaire (HAQ). Each VAS was followed by a question asking how much the respondent would be willing to pay on a monthly basis for a 50% improvement with the function in question. These were combined with later collected data on clinical status and use of RA-related health services. The average WTP varied greatly in the examined 20 different functions. The total WTP average on a 50% improved functional capacity amounted to <euro> 567.05 per month. Patients with lower functional capacity (HAQ 1.2 or more) were ready to contribute significantly (p < 0.001) more (705 euros/month) than those with better functional status (199 euros/month). Subjects, whose financial standing was better, reported a higher total WTP (r = 0.218, p < 0.01). On average, the total WTP of the respondents equaled 18.44% of the disposable net monthly income per person of the household. However, the variation was quite substantial. WTP among patients with rheumatoid arthritis was best depicted through the functional capacity of the patient, the possible time the patient had retired, and the global feeling of pain. In conclusion, monetary value is a concrete way of portraying subjective valuation. WTP method is suitable for assessing functional deficits of rheumatoid arthritis.

Citing Articles

From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices.

Boeri M, Szegvari B, Hauber B, Mange B, Mountian I, Schiff M Patient Prefer Adherence. 2019; 13:1093-1110.

PMID: 31371927 PMC: 6636455. DOI: 10.2147/PPA.S203775.


Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach.

Webers C, Essers I, van Tubergen A, Braun J, Heldmann F, Baraliakos X Arthritis Care Res (Hoboken). 2017; 70(4):608-616.

PMID: 28575536 PMC: 5901401. DOI: 10.1002/acr.23299.

References
1.
Slothuus U, Brooks R . Willingness to pay in arthritis: a Danish contribution. Rheumatology (Oxford). 2000; 39(7):791-9. DOI: 10.1093/rheumatology/39.7.791. View

2.
Fries J, Spitz P, Kraines R, HOLMAN H . Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23(2):137-45. DOI: 10.1002/art.1780230202. View

3.
Hewlett S, Carr M, Ryan S, Kirwan J, Richards P, Carr A . Outcomes generated by patients with rheumatoid arthritis: how important are they?. Musculoskeletal Care. 2006; 3(3):131-42. DOI: 10.1002/msc.3. View

4.
Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A . Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006; 65(9):1175-83. PMC: 1798296. DOI: 10.1136/ard.2005.046367. View

5.
Hewlett S, Smith A, Kirwan J . Values for function in rheumatoid arthritis: patients, professionals, and public. Ann Rheum Dis. 2001; 60(10):928-33. PMC: 1753375. DOI: 10.1136/ard.60.10.928. View